537 related articles for article (PubMed ID: 26378177)
81. Experimental evolution of an oncolytic vesicular stomatitis virus with increased selectivity for p53-deficient cells.
Garijo R; Hernández-Alonso P; Rivas C; Diallo JS; Sanjuán R
PLoS One; 2014; 9(7):e102365. PubMed ID: 25010337
[TBL] [Abstract][Full Text] [Related]
82. Expression of tumor antigens within an oncolytic virus enhances the anti-tumor T cell response.
Webb MJ; Sangsuwannukul T; van Vloten J; Evgin L; Kendall B; Tonne J; Thompson J; Metko M; Moore M; Chiriboga Yerovi MP; Olin M; Borgatti A; McNiven M; Monga SPS; Borad MJ; Melcher A; Roberts LR; Vile R
Nat Commun; 2024 Jun; 15(1):5442. PubMed ID: 38937436
[TBL] [Abstract][Full Text] [Related]
83. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.
Publicover J; Ramsburg E; Rose JK
J Virol; 2005 Nov; 79(21):13231-8. PubMed ID: 16227246
[TBL] [Abstract][Full Text] [Related]
84. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D
Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868
[TBL] [Abstract][Full Text] [Related]
85. Vesicular stomatitis virus: re-inventing the bullet.
Lichty BD; Power AT; Stojdl DF; Bell JC
Trends Mol Med; 2004 May; 10(5):210-6. PubMed ID: 15121047
[TBL] [Abstract][Full Text] [Related]
86. Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry.
Kobayashi S; Watanabe E; Ishigaki T; Ohno N; Yuji K; Nakano K; Yamochi T; Watanabe N; Tojo A; Watanabe T; Uchimaru K
Cancer Sci; 2015 May; 106(5):598-603. PubMed ID: 25703103
[TBL] [Abstract][Full Text] [Related]
87. A recombinant vesicular stomatitis virus encoding HIV-1 receptors and human OX40 ligand efficiently eliminates HIV-1-infected CD4-positive T cells expressing OX40.
Tsuruno C; Okuma K; Takahashi Y; Tanaka R; Tanaka Y; Takahama Y; Hamaguchi Y; Hamaguchi I; Yamaguchi K
Hum Immunol; 2011 Apr; 72(4):295-304. PubMed ID: 21262309
[TBL] [Abstract][Full Text] [Related]
88. Virus specific tolerance enhanced efficacy of cancer immuno-virotherapy.
Sobhanimonfared F; Bamdad T; Sadigh ZA; Choobin H
Microb Pathog; 2020 Mar; 140():103957. PubMed ID: 31891795
[TBL] [Abstract][Full Text] [Related]
89. Curcumin promotes the oncoltyic capacity of vesicular stomatitis virus for the treatment of prostate cancers.
Fehl DJ; Ahmed M
Virus Res; 2017 Jan; 228():14-23. PubMed ID: 27865863
[TBL] [Abstract][Full Text] [Related]
90. Localization of T helper cell epitopes in the vesicular stomatitis virus: the nucleoprotein is responsible for serotype cross-reactive T help.
Burkhart C; Freer G; Steinhoff U; Li Y; Bishop DH; Zinkernagel RM; Hengartner H
Viral Immunol; 1994; 7(3):103-11. PubMed ID: 7541205
[TBL] [Abstract][Full Text] [Related]
91. Replication-competent rhabdoviruses with human immunodeficiency virus type 1 coats and green fluorescent protein: entry by a pH-independent pathway.
Boritz E; Gerlach J; Johnson JE; Rose JK
J Virol; 1999 Aug; 73(8):6937-45. PubMed ID: 10400792
[TBL] [Abstract][Full Text] [Related]
92. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.
Wu Y; Lun X; Zhou H; Wang L; Sun B; Bell JC; Barrett JW; McFadden G; Biegel JA; Senger DL; Forsyth PA
Clin Cancer Res; 2008 Feb; 14(4):1218-27. PubMed ID: 18281557
[TBL] [Abstract][Full Text] [Related]
93. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.
Kottke T; Diaz RM; Kaluza K; Pulido J; Galivo F; Wongthida P; Thompson J; Willmon C; Barber GN; Chester J; Selby P; Strome S; Harrington K; Melcher A; Vile RG
Mol Ther; 2008 Dec; 16(12):1910-8. PubMed ID: 18827807
[TBL] [Abstract][Full Text] [Related]
94. Suppression of antiviral innate immunity by sunitinib enhances oncolytic virotherapy.
Jha BK; Dong B; Nguyen CT; Polyakova I; Silverman RH
Mol Ther; 2013 Sep; 21(9):1749-57. PubMed ID: 23732991
[TBL] [Abstract][Full Text] [Related]
95. Insertion of the human immunodeficiency virus CD4 receptor into the envelope of vesicular stomatitis virus particles.
Schubert M; Joshi B; Blondel D; Harmison GG
J Virol; 1992 Mar; 66(3):1579-89. PubMed ID: 1310767
[TBL] [Abstract][Full Text] [Related]
96. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
97. Humoral hypercalcemia of malignancy: severe combined immunodeficient/beige mouse model of adult T-cell lymphoma independent of human T-cell lymphotropic virus type-1 tax expression.
Richard V; Lairmore MD; Green PL; Feuer G; Erbe RS; Albrecht B; D'Souza C; Keller ET; Dai J; Rosol TJ
Am J Pathol; 2001 Jun; 158(6):2219-28. PubMed ID: 11395400
[TBL] [Abstract][Full Text] [Related]
98. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
[TBL] [Abstract][Full Text] [Related]
99. Vesicular stomatitis virus as a treatment for colorectal cancer.
Stewart JH; Ahmed M; Northrup SA; Willingham M; Lyles DS
Cancer Gene Ther; 2011 Dec; 18(12):837-49. PubMed ID: 21886191
[TBL] [Abstract][Full Text] [Related]
100. Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer.
Naik S; Galyon GD; Jenks NJ; Steele MB; Miller AC; Allstadt SD; Suksanpaisan L; Peng KW; Federspiel MJ; Russell SJ; LeBlanc AK
Mol Cancer Ther; 2018 Jan; 17(1):316-326. PubMed ID: 29158470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
